Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
Wang-Da Liu, Chien-Ching Hung, Jann-Tay Wang and 8 more
Journal of the Formosan Medical Association · 2021
doi:10.1016/j.jfma.2021.04.010 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.